Neogen (NEOG) Q1 2027 Earnings Report

The call was predominantly positive. Neogen reported broad-based revenue growth, improved adjusted EBITDA margins and free cash flow, raised fiscal 2027 guidance, advanced commercial and innovation initiatives, and reached an important Petrifilm validation milestone. Management also highlighted near-term growth timing effects, macroeconomic pressures, transition-related duplicative costs and a full-year EBITDA margin outlook roughly similar to fiscal 2026, but described these issues as understood and incorporated into its plans.

For fiscal year 2027, Neogen raised revenue guidance to $885 million to $890 million and adjusted EBITDA guidance to $181 million to $183 million, with the genomics business continuing to be included; the second quarter is expected to see the lowest level of core growth, first-half core growth is expected to be “in the range of approximately 3.5%,” and first-half adjusted EBITDA margin is expected to be “in line with the first quarter,” while full-year EBITDA margins are expected to be “roughly similar” to fiscal year '26. The company expects to expand adjusted EBITDA margins through progress in key operational efficiency programs, and maintains its view that both GAAP cash flow from operations and free cash flow will “increase meaningfully on a year-over-year basis”; the genomics divestiture is expected to receive a final decision by the end of December, with expected net proceeds of approximately $140 million, which would put net leverage below 3x at closing and closer to 2.5x by the end of the fiscal year. The Petrifilm manufacturing transfer is expected to begin the planned multi-quarter transfer next month, and after transitioning over through fiscal year '28, Neogen expects margin improvement of 200 to 300 basis points in FY '29, with improvements beginning in the first fiscal year and fully implemented in the second year.